MedPath

Diclofenac

Generic Name
Diclofenac
Brand Names
Aleve Arthritis Pain, Arthrotec, Cambia, Cataflam, Flector, Licart, Lofena, Pennsaid, Previdolrx Analgesic Pak, Salonpas Pain Relieving Patch, Solaraze, Voltaren, Voltaren Emulgel, Xrylix, Zipsor, Zorvolex
Drug Type
Small Molecule
Chemical Formula
C14H11Cl2NO2
CAS Number
15307-86-5
Unique Ingredient Identifier
144O8QL0L1

Overview

Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID). NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of phenylbutazone, mefenamic acid, and indomethacin. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with misoprostol to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the FDA in July 1988 under the trade name Voltaren, marketed by Novartis (previously Ciba-Geigy).

Indication

Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma. It is often used in combination with misoprostol as a gastro-protective agent in patients with high risk of developing NSAID-induced ulcers.

Associated Conditions

  • Actinic Keratosis (AK)
  • Acute Arthritis
  • Acute Gouty Arthritis
  • Acute Migraine
  • Acute Musculoskeletal Pain
  • Ankylosing Spondylitis (AS)
  • Common Cold
  • Fever
  • Gout
  • Inflammation
  • Inflammatory Disease of the Oral Cavity
  • Inflammatory Disease of the throat
  • Inflammatory Reaction of the Nerve
  • Joint Pain
  • Juvenile Idiopathic Arthritis (JIA)
  • Menstrual Distress (Dysmenorrhea)
  • Muscle Inflammation
  • Myalgia
  • Neuropathic Pain
  • Ocular Inflammation
  • Osteoarthritis (OA)
  • Osteoarthritis of the Knee
  • Pain
  • Pain caused by Rheumatism
  • Pericarditis
  • Photophobia
  • Postoperative Inflammatory Response
  • Postoperative pain
  • Primary Dysmenorrhoea
  • Radicular Pain
  • Rheumatism
  • Rheumatoid Arthritis
  • Seasonal Allergic Conjunctivitis
  • Spinal pain
  • Tendon pain
  • Vertebral column pain
  • Acute Musculoskeletal injury
  • Acute, moderate, severe Pain, Inflammatory
  • Localized soft tissue rheumatism
  • Mild to moderate joint pain
  • Mild to moderate pain
  • Minor pain
  • Perioperative miosis

Research Report

Published: Jun 4, 2025

Diclofenac: A Comprehensive Pharmacological and Clinical Review

1. Introduction to Diclofenac

1.1. Overview and Summary

Diclofenac is a well-established phenylacetic acid derivative classified as a non-steroidal anti-inflammatory drug (NSAID).[1] It is primarily utilized for the management of signs and symptoms associated with various arthritic conditions, including osteoarthritis and rheumatoid arthritis.[1] Its therapeutic applications extend to ankylosing spondylitis and a range of other painful states, such as menstrual cramps (primary dysmenorrhea) and acute migraine attacks.[2] The pharmacological profile of diclofenac is characterized by its potent anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) activities.[3]

The broad spectrum of indications for diclofenac underscores its efficacy in conditions where prostaglandins play a significant pathogenic role. Prostaglandins are key mediators in inflammation, pain sensitization, and fever development. By inhibiting their synthesis, diclofenac offers relief across a diverse array of clinical scenarios. Its utility in both chronic inflammatory diseases like arthritis and acute painful conditions such as migraines highlights its versatility as a therapeutic agent.[1] This versatility is a direct consequence of its fundamental mechanism of action as an NSAID, which targets the cyclooxygenase (COX) enzymes responsible for prostaglandin production. However, this same mechanism also underpins its potential for adverse effects, particularly concerning the gastrointestinal and cardiovascular systems, which are significant enough to warrant boxed warnings from regulatory authorities like the U.S. Food and Drug Administration (FDA).[3] The widespread and long-standing use of diclofenac implies a considerable clinical impact in pain and inflammation management. Concurrently, this extensive use necessitates a comprehensive understanding and careful consideration of its

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/08/20
Not Applicable
Recruiting
2025/08/03
Not Applicable
Not yet recruiting
Mariam Hesham Mahmoud Abdelfattah Eissa
2025/07/28
Not Applicable
Completed
2025/07/17
Not Applicable
Recruiting
2025/07/17
Not Applicable
Recruiting
Air Force Military Medical University, China
2025/05/25
Phase 1
Not yet recruiting
Synartro AB
2025/04/22
Not Applicable
Recruiting
2025/04/09
Phase 4
Active, not recruiting
Haydarpasa Numune Training and Research Hospital
2025/04/01
Not Applicable
Recruiting
The Second Affiliated Hospital of Hainan Medical University
2025/02/25
Not Applicable
Completed
Assumpta Nnenna Nweke

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
A-S Medication Solutions
50090-4018
TOPICAL
16.05 mg in 1 mL
9/17/2018
Proficient Rx LP
71205-618
TOPICAL
10 mg in 1 g
5/2/2022
medsource pharmaceuticals
45865-964
TOPICAL
16.05 mg in 1 mL
12/30/2019
Bryant Ranch Prepack
71335-9720
ORAL
50 mg in 1 1
12/8/2022
A-S Medication Solutions
50090-4621
TOPICAL
10 mg in 1 g
2/5/2021
Rebel Distributors Corp
21695-791
TOPICAL
10 mg in 1 g
12/18/2008
Bryant Ranch Prepack
71335-0371
TOPICAL
10 mg in 1 g
9/17/2018
Asclemed USA, Inc.
76420-012
TOPICAL
16.05 mg in 1 mL
10/12/2022
Preferred Pharmaceuticals Inc.
68788-9435
TOPICAL
30 mg in 1 g
6/12/2023
Preferred Pharmaceuticals Inc.
68788-7103
ORAL
75 mg in 1 1
5/4/2023

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
REMETHAN GEL 1%
SIN08561P
GEL
10 mg/g
2/5/1996
VOREN SUPPOSITORY 12.5 mg
SIN06614P
SUPPOSITORY
12.5 mg
10/12/1991
REMAFEN TABLET 25 mg
SIN05990P
ENTERIC COATED TABLET
25 mg
5/27/1991
NEODOL INJECTION 25 mg/ml
SIN09444P
INJECTION
25 mg/ml
7/16/1997
DICLOGEL 1% w/w
SIN09170P
GEL
1% w/w
1/25/1997
RHEWLIN FORTE TABLETS 50 mg
SIN05560P
ENTERIC COATED TABLET
50 mg
3/7/1991
VOLTAREN 25 SUPPOSITORY 25 mg
SIN05467P
SUPPOSITORY
25 mg
2/22/1991
FENAC-50 TABLET 50 mg
SIN09312P
TABLET, FILM COATED
50 mg
4/25/1997
SALONPAS DICLOFENAC GEL 1%
SIN16418P
GEL
1g/100g
1/17/2022
ULTRAFEN 50 SUPPOSITORY 50 mg
SIN10519P
SUPPOSITORY
50 mg
12/8/1998

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
SANDOZ DICLOFENAC MISOPROSTOL
02400596
Tablet - Oral
50 MG
N/A
DICLOFENAC EC
sanis health inc
02352397
Tablet (Enteric-Coated) - Oral
50 MG
6/15/2010
PENTA-DICLOFENAC - 50MG
pentapharm ltd.
02229592
Tablet (Enteric-Coated) - Oral
50 MG
6/6/1997
VOLTAREN SR
novartis pharmaceuticals canada inc
00782459
Tablet (Extended-Release) - Oral
75 MG
12/31/1989
VOLTAREN
novartis pharmaceuticals canada inc
00632732
Suppository - Rectal
100 MG
12/31/1985
SANDOZ-DICLOFENAC
02261960
Tablet (Delayed-Release) - Oral
50 MG
2/2/2006
RHO-DICLOFENAC
rhoxalpharma inc
02236725
Tablet (Enteric-Coated) - Oral
50 MG
N/A
PMS-DICLOFENAC-MISOPROSTOL
02413469
Tablet (Delayed-Release) - Oral
50 MG
12/11/2018
PMS-DICLOFENAC
02231502
Tablet (Enteric-Coated) - Oral
25 MG
11/28/1997
NTP-DICLOFENAC POTASSIUM
teva canada limited
02346281
Tablet - Oral
50 MG
N/A

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
DOLO-VOLTAREN 46,5 MG COMPRIMIDOS DISPERSABLES
Novartis Farmaceutica S.A.
61440
COMPRIMIDO DISPERSABLE
Medicamento Sujeto A Prescripción Médica
Commercialized
DOLOTREN 46,5 mg comprimidos dispersables
60068
COMPRIMIDO DISPERSABLE
Medicamento Sujeto A Prescripción Médica
Commercialized

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.